Table 3.
Univariate analysis for the 5-year and 10-year DFS in patients (n = 81) with head and neck AdCC
| Parameter | n | 5-year | p | 10-year | p | ||
|---|---|---|---|---|---|---|---|
| DFS (95% CI) | HR (95% CI) | DFS (95% CI) | HR (95% CI) | ||||
| Age | |||||||
| ≤ 50 years | 38 | 60.53 (43.29–74.00) | 0.88 (0.43–1.79) | 0.734 | 50.00 (33.40–64.52) | 1.01 (0.55–1.86) | 0.954 |
| > 50 years | 43 | 62.79 (46.63–75.29) | 46.51 (31.24–60.44) | ||||
| Sex | |||||||
| Male | 37 | 64.86 (47.30–77.86) | 1.11 (0.54–2.28) | 0.759 | 45.95 (29.55–60.88) | 0.91 (0.49–1.67) | 0.774 |
| Female | 44 | 59.09 (43.19–71.91) | 50.00 (34.59–63.60) | ||||
| Primary site | |||||||
| Major SG | 43 | 67.44 (51.31–79.25) | 1.46 (0.72–2.97) | 0.288 | 53.49 (37.65–66.98) | 1.37 (0.74–2.51) | 0.305 |
| Minor SG/other sites | 38 | 55.26 (38.26–69.34) | 42.11 (26.42–57.00) | ||||
| Tumor size (T) | |||||||
| T1/T2 | 38 | 78.95 (62.29–88.87) | 3.23 (1.44–7.24) | 0.002 | 76.32 (59.42–86.90) | 4.86 (2.31–10.23) | < 0.001 |
| T3/T4 | 43 | 46.51 (31.24–60.44) | 23.26 (12.05–36.60) | ||||
| Lymph node metastasis (N) | |||||||
| N0 | 69 | 63.77 (51.27–73.86) | 1.55 (0.63–3.78) | 0.329 | 52.17 (39.82–63.15) | 1.85 (0.88–3.88) | 0.094 |
| N1/N2/N3 | 12 | 50.00 (20.85–73.61) | 25.00 (6.01–50.48) | ||||
| Distant metastasis (M) | |||||||
| M0 | 67 | 68.66 (56.09–78.30) | 3.07 (1.44–6.54) | 0.002 | 58.21 (45.51–68.94) | 4.30 (2.21–8.36) | < 0.001 |
| M1 | 14 | 28.57 (8.83–52.37) | 7.14 (0.45–27.52) | ||||
| Clinical stage | |||||||
| I/II | 32 | 84.38 (66.46–93.18) | 4.31 (1.65–11.26) | 0.001 | 84.38 (66.46–93.18) | 7.44 (2.90–19.05) | < 0.001 |
| III/IV | 49 | 46.94 (32.59–60.04) | 24.49 (13.60–37.08) | ||||
| Histopathological pattern | |||||||
| Tubular/cribriform | 62 | 64.52 (51.28–75.01) | 1.49 (0.68–3.24) | 0.306 | 54.84 (41.69–66.20) | 1.91 (1.00–3.64) | 0.042 |
| Solid | 19 | 52.63 (28.72–71.88) | 26.32 (9.58 – 46.77) | ||||
| Perineural invasion | |||||||
| Absent | 29 | 72.41 (52.34–85.13) | 1.67 (0.75–3.75) | 0.200 | 65.52 (45.41–79.73) | 2.01 (0.99–4.11) | 0.047 |
| Present | 52 | 55.77 (41.32–67.99) | 38.46 (25.43–51.34) | ||||
| Surgical margins | |||||||
| Negative | 44 | 84.09 (69.50–92.08) | 6.01 (2.57–14.01) | < 0.001 | 81.82 (66.92–90.46) | 10.04 (4.56–22.10) | < 0.001 |
| Positive | 37 | 35.14 (20.40–50.25) | 8.11 (2.09–19.57) | ||||
| Treatment | |||||||
| Surgery | 12 | 75.00 (40.84–91.17) | 1.53 (0.86–2.70) | 0.318 | 75.00 (40.84–91.17) | 2.23 (1.32–3.75) | 0.004 |
| Surgery + RT | 36 | 66.67 (48.83–79.50) | 61.11 (43.35–74.82) | ||||
| Surgery + RT + ChT | 26 | 53.85 (33.29–70.58) | 23.08 (9.38–40.31) | ||||
Seven cases were not included in analysis of association between DFS and treatment: two patients submitted to surgery and ChT; four patients submitted to RT and ChT; and one submitted to ChT
Bold values indicate statistically significant results
DFS disease-free survival, CI confidence interval, HR hazard ratio, SG salivary gland, RT radiotherapy, ChT chemotherapy